DBV Technologies DBVT 深 滬
等待開盤 08-21 09:30:00 美东时间
14.24
-0.540
-3.65%
華盛通- 最 高14.7099
- 今 開14.42
- 成交量 11.93万股
- 最 低 14.18
- 昨 收 14.78
- 總市值 8.95亿
- 52周最高 26.185
- 市盈率 靜 --
- 換手率 0.19%
- 52周最低 8.70
- 委 比 -99.89%
- 總股本 6284.58万
- 歷史最高 505.70
- 量 比 0.58
- 振 幅 3.59%
- 歷史最低 3.15
- 每 手 1
- 風險率 4.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
DBV Technologies announced the sale of approximately $50 million of ADSs through its At-The-Market (ATM) Program on Nasdaq. The ADSs, representing new ordinary shares, were sold to RA Capital Management, L.P. at a price of $13.67 per ADS, reflecting a 0.15% discount to the closing price on Euronext Paris. The issuance will dilute existing shareholders by approximately 5.82% and the new shares will represent 6.18% of the existing shares on Euronex...
07-30 21:40
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
DBV Technologies filed a new shelf registration statement with the SEC for an at-the-market (ATM) offering of up to $150 million in American Depositary Shares (ADS). Each ADS represents five ordinary shares. The ATM Program, established under a 2025 sales agreement with Citizens JMP Securities, allows the company to sell ADSs to qualified investors, with proceeds to be used for manufacturing expansion, clinical trials for peanut allergy treatment...
07-17 21:00
DBV Technologies Q2 EPS $(0.12) Misses $(0.10) Estimate, Sales $700.000K Miss $1.391M Estimate
DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 61.29 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $700.000 thous...
07-17 04:03
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
DBV Technologies reported Q2 and H1 2026 financial results and business updates. Key highlights include ongoing productive engagement with the FDA for the VIASKIN® Peanut Patch BLA submission in children aged 4-7, cash of $174.9 million as of June 30, 2026, and a conference call on July 16, 2026. The company has made progress in regulatory and clinical execution, including advancing the BLA submission, closing recruitment for the COMFORT Toddlers...
07-16 20:01
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55
Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $47 to $55.
06-30 22:16
DBV Advances VIASKIN Peanut Patch Toward FDA Submission
An announcement from DBV Technologies SA – American ( ($DBVT) ) is now availabl...
06-30 04:50
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
DBV Technologies has updated on the BLA submission for the VIASKIN® Peanut Patch in children aged 4-7 years, confirming no additional data is needed from the FDA. The company plans to submit the BLA in Q3 2026 after incorporating FDA feedback. A conference call is scheduled for June 29, 2026, at 5:00pm ET.
06-29 20:00
